Table 2.
KIR and KIR ligands in controls and patients with plasma cell dyscrasia.
| Controls (n = 286 ) | MGUS (n = 86 ) | SMM (n = 25 ) | MM (n = 53 ) | MM with ISS>I (n = 41 ) | |
|---|---|---|---|---|---|
| KIR gene frequency1 | n (%) | n (%) | n (%) | n (%) | n (%) |
| 2DL1 | 278 (97.2%) | 83 (96.5%) | 23 (92.0%) | 46 (86.8%)2 | 34 (82.9%)2 |
| 2DL2 | 180 (62.9%) | 48 (55.8%) | 11 (44.0%) | 29 (54.7%) | 25 (61.0%) |
| 2DL3 | 251 (87.8%) | 74 (86.0%) | 21 (84.0%) | 40 (75.5%)3 | 28 (68.3%)3 |
| 2DL5 | 146 (51.0%) | 51 (59.3%) | 11 (44.0%) | 28 (52.8%) | 23 (56.1%) |
| 3DL1 | 274 (98.8%) | 82 (95.3%) | 24 (96.0%) | 47 (88.7%)4 | 36 (87.8%)4 |
| 2DS1 | 104 (36.4%) | 37 (43.5%) | 7 (28.0%) | 20 (37.7%) | 16 (39.0%) |
| 2DS2 | 179 (62.6%) | 48 (55.8%) | 11 (44.0%) | 31 (58.5%)5 | 27 (65.9%)5 |
| 2DS3 | 94 (33.0%) | 32 (37.2%) | 8 (32.0%) | 16 (30.2%) | 14 (34.1%) |
| 2DS4 | 274 (98.8%) | 82 (95.3%) | 24 (96.0%) | 47 (88.7%)4 | 36 (87.8%)4 |
| 2DS5 | 76 (26.6%) | 31 (36.5%) | 5 (20.0%) | 16 (30.2%) | 13 (31.7%) |
| 3DS1 | 111 (38.8%) | 37 (43.0%) | 7 (28.0%) | 22 (41.5%) | 17 (41.5%) |
| iKIR2D genotypes | |||||
| 2DL1+L2+L3+ | 142 (49.7%) | 36 (41.9%) | 7 (28.0%)6 | 16 (30.2%)6 | 12 (29.3%)6 |
| 2DL1+L2+L3− | 26 (9.1%) | 9 (10.5%) | 2 (8.0%) | 6 (11.3%) | 6 (14.6%) |
| 2DL1+L2−L3+ | 110 (38.5%) | 38 (44.2%) | 14 (56.0%) | 24 (45.3%) | 16 (39.0%) |
| 2DL1−L2+L3− | 8 (2.8%) | 3 (3.5%) | 2 (8.0%) | 7 (13.2%)7 | 7 (17.1%)7 |
| KIR genotype | |||||
| AA | 76 (26.3%) | 16 (18.6%) | 9 (36.0%) | 13 (24.5%) | 8 (19.5%) |
| Bx | 211 (73.8%) | 70 (81.4%) | 16 (64.0%) | 40 (75.5%) | 33 (80.5%) |
| KIR ligands | |||||
| C1C1 | 95 (33.3%) | 25 (29.1%) | 8 (32.0%) | 21 (39.6%) | 15 (33.6%) |
| C1C2 | 136 (47.6%) | 40 (46.5%) | 14 (56.0%) | 24 (45.2%) | 22 (56.3%) |
| C2C2 | 55 (19.2%) | 21 (24.4%) | 3 (12.0%) | 8 (15.1%) | 4 (9.75%) |
| Bw4 | 230 (80.4%) | 62 (79.5%) | 20 (80.0%) | 42 (79.2%) | 32 (78.0%) |
| A3/A11 | 87 (32.4%) | 25 (32.1%) | 5 (20.0%) | 16 (30.2%) | 13 (31.7%) |
Framework genes are not considered (3DL2, 3DL3, 2DL4, 3DP1).
Control vs. MM (p < 0.01; Pc < 0.05; OR = 0.19); Control vs. MM with ISS > I (p < 0.001; Pc < 0.01; OR = 0.14); MGUS vs. MM (p < 0.05; Pc > 0.05; OR = 0.24) and MGUS vs. MM with ISS >I (p < 0.01; Pc > 0.05; OR = 0.18).
Control vs. MM (p < 0.05; Pc >0.05; OR = 0.41); Control vs. MM with (ISS >I p< 0.01; Pc< 0.05; OR = 0.29); MGUS vs. MM with ISS >I (p < 0.05; Pc >0.05; OR = 0.35).
Control vs. MM (p < 0.05; Pc >0.05; OR = 0.31) and Control vs. MM with ISS >I (p < 0.05; Pc >0.05; OR = 0.29).
KIR2DL2−S2+ dissociated genotype was found in two MM with ISS > I.
Control vs. SMM (p < 0.05; Pc >0.05; OR = 0.39); Control vs. MM (p < 0.01; Pc < 0.05; OR = 0.44) and Control vs. MM ISS > I (p < 0.05; Pc > 0.05; OR = 0.42).
Control vs. MM (p < 0.01; Pc < 0.05; OR = 5.23); Control vs. MM with ISS > I (p < 0.001; Pc < 0.01; OR = 7.15); MGUS vs. MM (p < 0.05; Pc > 0.05; OR = 4.2) and MGUS vs. MM with ISS>I (p < 0.05; Pc >0.05; OR = 5.88).